Mental Fatigue and Performance in Young Soccer Players

May 13, 2025 updated by: Ersan Arslan, Tokat Gaziosmanpasa University

Investigation of the Effects of Mental Fatigue on Physical Performance and Perceived Psychophysiological Reactions in Young Soccer Players: A Field Based Study

The study employed a randomized, parallel-group, between-subjects design in which participants were assigned to either the MF+ or MF- condition and completed a single testing session accordingly. All test sessions were conducted on synthetic turf pitches and comprised three stages of testing, which included assessments of aerobic and anaerobic endurance, jumping, agility, and balance. During the familiarization session, players were briefed on the study procedures, practiced the main tasks, and became accustomed to the equipment and environment used during the intervention. During the MF+ session, prior to each physical testing stage, participants completed a 30-minute Color-word Stroop task (CST) to induce MF. To minimize external influence, players were not prompted or verbally encouraged during testing. Immediately, after each session, ratings of perceived exertion (RPE 6--20) were recorded using the category-level Borg scale (29), and enjoyment was assessed using the exercise enjoyment scale, a bipolar instrument consisting of eight items scored on a 1-7 Likert scale.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The study employed a randomized, parallel-group, between-subjects design in which participants were assigned to either the MF+ or MF- condition and completed a single testing session accordingly. Players were recommended to sleep for at least 7-8 hours, refrain from exercising at moderate to high intensity, and avoid consuming alcoholic or caffeinated beverages during the 24 hours before the intervention. Indoor and outdoor temperatures (25-28°C) and humidity levels (35-40%) were kept consistent across all intervention sessions. All test sessions were conducted on synthetic turf pitches and comprised three stages of testing, which included assessments of aerobic and anaerobic endurance, jumping, agility, and balance. During the familiarization session, players were briefed on the study procedures, practiced the main tasks, and became accustomed to the equipment and environment used during the intervention. During the MF+ session, prior to each physical testing stage, participants completed a 30-minute Color-word Stroop task (CST) to induce MF. Four color words (red, blue, green, and yellow) were randomly printed, and participants were required to verbally name the color of each word. During the control (MF-) session, prior to each physical testing stage, participants watched emotionally neutral documentaries for 30 minutes. Each testing session began with a standardized 15-minute warm-up, consisting of 5 minutes of low- to moderate-intensity running followed by 10 minutes of upper- and lower-extremity-specific dynamic stretching, mobility exercises, and change-of-direction drills. To minimize external influence, players were not prompted or verbally encouraged during testing. Immediately, after each session, ratings of perceived exertion (RPE 6--20) were recorded using the category-level Borg scale, and enjoyment was assessed using the exercise enjoyment scale, a bipolar instrument consisting of eight items scored on a 1-7 Likert scale.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
16

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Tokat, Turkey, 6000
        • Tokat Gaziosmanpaşa Universty

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Being healthy
  • Male soccer players
  • Willing to maintain the intervention for all sessions

Exclusion Criteria:

  • Being under 14 years old
  • Having a chronic disease
  • Contraindications for exercise

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: Mental Fatigue (MF+)
During the MF+ session, before each physical testing phase, participants completed a 30-min Colour Word Stroop task (CST) to trigger
Other: MF+
During the MF+ session, before each physical testing phase, participants completed a 30-min Colour Word Stroop task (CST) to trigger MF. The paper-based version of the CST was completed in quiet rooms following the same protocol as in previous studies. This prolonged cognitive task was reported to require sustained attention and automatic response inhibition and effectively induced MF through cognitive manipulation. ThyIt had ben Four colour words (red, blue, green and yellow) were randomly printed and participants were asked to verbalise the colour of each word.
Other: Control (MF-)
Control
Other: MF-
During the control session, before each physical testing phase, participants watched emotionally neutral documentaries for 30 min.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Aerobic performance assessment
Time Frame: From baseline to the end of measurement at 1 day
The test consisted of shuttle runs between two landmarks placed 20 metres apart, and athletes were required to complete a short active recovery period by running or walking within 10 seconds after each shuttle run. The testing protocol typically includes a standardised warm-up followed by progressive shuttle runs until exhaustion. The distance travelled or the level reached before exhaustion is used to measure performance. The test was carried out on an artificial turf field according to the recommended procedures.
From baseline to the end of measurement at 1 day
Countermovement jump performance assessment
Time Frame: From baseline to the end of measurement at 1 day
Countermovement jump tests with arms free (CMJf) tests were used to test the performance of the players in the vertical jump test. Each player's CMJf jump height was measured via Optojump photoelectric cells (Microgate, Bolzano, Italy). To ensure proper recovery and reduce fatigue, players were given a passive rest period of 2 minutes between consecutive trials in the same jump test. In addition, there was a rest period of 5 min between the different jump tests.
From baseline to the end of measurement at 1 day
Agility performance assessment
Time Frame: From baseline to the end of measurement at 1 day
Players completed three Zig-Zag agility tests with a ball (ZZwB) on a synthetic turf field. Each set was followed by a 3-minute recovery period, and the fastest time recorded from all sets was considered to be the performance of the test. The ZZwB trail comprises four 5-meter sections designed at 100° angles. In a previous study by Mirkov et al. (34), a coefficient of variation of 21.12%, intraclass correlation coefficients (ICCs) of 0.81 and 0.84, and typical measurement errors of 0.21 and 0.098 were reported for ZZwB.
From baseline to the end of measurement at 1 day
Balence performance assessment
Time Frame: From baseline to the end of measurement at 1 day
The Y balance test was used for balance measurements. Before the test, the length of both legs of each player was measured via a standard tape measure from the anterior superior iliac spine to the most distal medial malleolus in the supine position. The test, consisting of three different directions of movement (anterior, posteromedial, and posterolateral), was used to assess dynamic balance with a single-leg stance while reaching these directions. After six trials on each foot for familiarization, each player performed three successful reaches 15 s apart. After the test, the composite score (CS) was calculated via the following formula (37): CS = [(maximum anterior reach + maximum posteromedial reach + maximum posterolateral reach)/(leg length × 3)] × 100.
From baseline to the end of measurement at 1 day
Anaerobic Endurance assessment
Time Frame: From baseline to the end of measurement at 1 day
A three-corner run test (TCRT) was used to assess the speed and anaerobic endurance of the players. After the start signal, the players ran to a flagpole 80 m away from the start. The players then turned to the left side and ran to a flagpole, 20 m away from flagpole. After that, the players returned to flagpole 82.4 m from the start. Finally, turning to the right, the players ran to finish line and crossed the line to end the test.
From baseline to the end of measurement at 1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Tokat Gaziosmanpasa University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 27, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 30, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 13, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 13, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 21, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 21, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 13, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • UGaziosmanpasa-3

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings